-
EP3883579
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3883579
| EP3883579 - COMBINATION THERAPY INCLUDING A KRAS-G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS [Right-click to bookmark this link] | |||
| Former [2021/39] | <SUP2/>? <SUB2/>?G12C? ?COMBINATION THERAPY INCLUDING A KRASINHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | ||
| [2022/21] | Status | The patent has been granted Status updated on 21.11.2025 Database last updated on 10.03.2026 | |
| Former | Grant of patent is intended Status updated on 09.06.2025 | ||
| Former | Examination is in progress Status updated on 13.10.2023 | ||
| Former | Request for examination was made Status updated on 27.08.2021 | ||
| Former | The international publication has been made Status updated on 30.05.2020 | Most recent event Tooltip | 21.11.2025 | (Expected) grant | published on 24.12.2025 [2025/52] | Applicant(s) | For all designated states Amgen Inc. One Amgen Center Drive Thousand Oaks CA 91320 / US | [2021/39] | Inventor(s) | 01 /
LIPFORD, James Russell One Amgen Center Drive Legal Dept - Patent Operations MS 28-5-A Thousand Oaks, CA 91320-1799 / US | 02 /
CANON, Jude Robert One Amgen Center Drive Legal Dept - Patent Operations MS 28-5-A Thousand Oaks, CA 91320-1799 / US | 03 /
SAIKI, Anne Y. One Amgen Center Drive Legal Dept - Patent Operations MS 28-5-A Thousand Oaks, CA 91320-1799 / US | 04 /
REX, Karen Louise One Amgen Center Drive Legal Dept - Patent Operations MS 28-5-A Thousand Oaks, CA 91320-1799 / US | [2021/39] | Representative(s) | Murgitroyd & Company 165-169 Scotland Street Glasgow G5 8PL / GB | [2025/52] |
| Former [2021/39] | Murgitroyd & Company Murgitroyd House 165-169 Scotland Street Glasgow G5 8PL / GB | Application number, filing date | 19886683.2 | 18.11.2019 | [2021/39] | WO2019US62064 | Priority number, date | US201862769355P | 19.11.2018 Original published format: US 201862769355 P | US201962821376P | 20.03.2019 Original published format: US 201962821376 P | US201962865819P | 24.06.2019 Original published format: US 201962865819 P | [2021/39] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2020106647 | Date: | 28.05.2020 | Language: | EN | [2020/22] | Type: | A2 Application without search report | No.: | EP3883579 | Date: | 29.09.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 28.05.2020 takes the place of the publication of the European patent application. | [2021/39] | Type: | B1 Patent specification | No.: | EP3883579 | Date: | 24.12.2025 | Language: | EN | [2025/52] | Search report(s) | International search report - published on: | EP | 26.11.2020 | Classification | IPC: | A61K31/555, A61K31/506, A61K31/519, A61K45/06, A61P35/00, A61K39/395, C07K16/28 | [2021/39] | CPC: |
A61K45/06 (EP,CN,IL,KR);
C07K16/2818 (EP,IL,US);
A61K31/519 (EP,CN,IL,KR,US);
A61K31/444 (KR);
A61K31/506 (EP,CN,IL);
A61K31/555 (EP,CN,IL,US);
A61K39/3955 (EP,IL);
A61K39/39558 (CN);
A61K39/39566 (CN);
| C-Set: |
A61K31/506, A61K2300/00 (CN,EP);
A61K31/519, A61K2300/00 (CN,EP);
A61K31/555, A61K2300/00 (EP,CN);
A61K39/39558, A61K2300/00 (CN); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/39] | Extension states | BA | 26.05.2021 | ME | 26.05.2021 | Validation states | MA | 26.05.2021 | TN | 26.05.2021 | Title | German: | KOMBINATIONSTHERAPIE, EINSCHLIESSLICH EINES KRAS-G12C-INHIBITORS UND EINES ODER MEHRERER ZUSÄTZLICHER PHARMAZEUTISCHER WIRKSTOFFE FÜR DIE BEHANDLUNG VON KREBS | [2025/32] | English: | COMBINATION THERAPY INCLUDING A KRAS-G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | [2025/32] | French: | POLYTHÉRAPIE INCLUANT UN INHIBITEUR DE KRAS G12C ET UN OU PLUSIEURS PRINCIPES PHARMACEUTIQUEMENT ACTIFS SUPPLÉMENTAIRES POUR LE TRAITEMENT DE CANCERS | [2025/32] |
| Former [2021/39] | KOMBINATIONSTHERAPIE MIT EINEM KRASG12C-INHIBITOR UND EINEM ODER MEHREREN ZUSÄTZLICHEN PHARMAZEUTISCHEN WIRKSTOFFEN ZUR BEHANDLUNG VON KREBSERKRANKUNGEN | ||
| Former [2021/39] | <SUP2/>? <SUB2/>?G12C? ?COMBINATION THERAPY INCLUDING A KRASINHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | ||
| Former [2021/39] | <SUP2/>? <SUB2/>?G12C? ?POLYTHÉRAPIE COMPRENANT UN INHIBITEUR DE KRASET UN OU PLUSIEURS PRINCIPES PHARMACEUTIQUEMENT ACTIFS SUPPLÉMENTAIRES POUR LE TRAITEMENT DE CANCERS | Biological material | This application mentions deposited biological material, check the file for details | Entry into regional phase | 26.05.2021 | National basic fee paid | 26.05.2021 | Designation fee(s) paid | 26.05.2021 | Examination fee paid | Examination procedure | 26.05.2021 | Examination requested [2021/39] | 26.05.2021 | Date on which the examining division has become responsible | 13.12.2021 | Amendment by applicant (claims and/or description) | 13.10.2023 | Despatch of a communication from the examining division (Time limit: M06) | 10.04.2024 | Reply to a communication from the examining division | 10.06.2025 | Communication of intention to grant the patent | 08.10.2025 | Fee for grant paid | 08.10.2025 | Fee for publishing/printing paid | 08.10.2025 | Receipt of the translation of the claim(s) | Divisional application(s) | EP25207118.8 | Fees paid | Renewal fee | 21.10.2021 | Renewal fee patent year 03 | 22.11.2022 | Renewal fee patent year 04 | 22.11.2023 | Renewal fee patent year 05 | 21.11.2024 | Renewal fee patent year 06 | 19.11.2025 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XYI] WO2016044772 (ARAXES PHARMA LLC et al.) | [XYI] WO2018119183 (AMGEN INC et al.) | [XY] EP3401314 (ARAXES PHARMA LLC et al.) | [XPY] WO2018217651 (AMGEN INC et al.) | by applicant | WO9633172 | WO9627583 | EP0818442 | EP1004578 | WO9807697 | WO9803516 | WO9834918 | WO9834915 | WO9833768 | WO9830566 | EP0606046 | EP0931788 | WO9005719 | WO9952910 | WO9952889 | WO9929667 | WO9907675 | EP1786785 | EP1181017 | US2009012085 | US5863949 | US5861510 | EP0780386 | US6258812 | US2003105091 | WO0137820 | US6235764 | WO0132651 | US6630500 | US6515004 | US6713485 | US5521184 | US5770599 | US5747498 | WO02068406 | WO02066470 | WO02055501 | WO2004005279 | WO2004007481 | WO2004007458 | WO2004009784 | WO02059110 | WO9945009 | WO0059509 | WO9961422 | US5990141 | WO0012089 | WO0002871 | US2003162712 | US6413932 | US6727225 | US2002042368 | US5981245 | US5728813 | US5969110 | US6596852 | US6232447 | US6057124 | EP0770622 | US5712291 | US5892112 | US5792783 | EP0970070 | JPH02233610 | WO2011031842 | EP0520722 | EP0566226 | WO9633980 | WO9630347 | EP0787772 | WO9730034 | WO9730044 | WO9738994 | WO9749688 | EP0837063 | WO9802434 | WO9738983 | WO9519774 | WO9519970 | WO9713771 | WO9802437 | WO9802438 | WO9732881 | DE19629652 | WO9833798 | WO9732880 | EP0682027 | WO9702266 | WO9727199 | WO9807726 | WO9734895 | WO9631510 | WO9814449 | WO9814450 | WO9814451 | WO9509847 | WO9719065 | WO9817662 | US5789427 | US5650415 | US5656643 | WO9935146 | WO9935132 | WO9907701 | WO9220642 | WO0206213 | WO2008153947 | WO2010151791 | WO2010151737 | WO2010151735 | WO2010151740 | WO2008118455 | WO2008118454 | WO2008118468 | US2010331293 | US2010331306 | US2009023761 | US2009030002 | US2009137581 | US2009054405 | US2009163489 | US2010273764 | US2011092504 | WO2010108074 | WO2006044453 | WO2009036082 | US5573001 | WO2006122806 | WO2008070740 | WO2010126895 | WO2010132598 | WO2010096314 | WO9409010 | WO9802441 | WO0114387 | WO2005005434 | US5258389 | WO9205179 | US5118677 | US5118678 | US5100883 | US5151413 | US5120842 | WO9311130 | WO9402136 | WO9402485 | WO9514023 | WO9516691 | WO9641807 | US5256790 | WO2005016252 | US60528340 | US7354944 | US7700636 | US7919514 | US7514566 | US2009270445 | US7919504 | US7897619 | WO2010083246 | WO2005011700 | US6656963 | JP2006309606 | WO2006121168 | US6111090 | EP0090505 | US8586023 | WO2010003118 | WO2011090754 | US7025962 | EP1947183 | US7812135 | US8388967 | US8591886 | EP1866339 | WO2011028683 | WO2013039954 | WO2005007190 | WO2007133822 | WO2005055808 | WO9940196 | WO0103720 | WO9920758 | WO2006083289 | WO2005115451 | US7618632 | WO2011051726 | WO2009085185 | US2011097305 | WO2018119183 | US201815984855 | US201762509629 | US201862768802 | "Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO, pages: 1435 - 712 | JANEWAY ET AL.: "Immunobiology: The Immune System in Health and Disease", 1999, ELSEVIER SCIENCE LTD./GARLAND PUBLISHING, article "Structure of the Antibody Molecule and the Immunoglobulin Genes" | KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE N.I.H. | CHOTHIALESK: "Bioreversible Carriers in Drug Design", vol. 196, 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS, pages: 901 - 917 | CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 883 | SHIMAMOTO ET AL., MABS, vol. 4, no. 5, 2012, pages 586 - 591 | SPIESS ET AL., MOLECULAR IMMUNOLOGY, vol. 67, no. 2, 2015, pages 97 - 106 | TRAXLER, P., EXP. OPIN. THER. PATENTS, vol. 8, no. 12, 1998, pages 1599 - 1625 | MODJTAHEDI, H. ET AL., BR. J. CANCER, vol. 67, 1993, pages 247 - 253 | TERAMOTO, T. ET AL., CANCER, vol. 77, 1996, pages 639 - 645 | GOLDSTEIN ET AL., CLIN. CANCER RES., vol. 1, 1995, pages 1311 - 1318 | HUANG, S. M. ET AL., CANCER RES., vol. 59, no. 8, 1999, pages 1236 - 1243 | BARNETT ET AL., BIOCHEM. J., vol. 385, 2005, pages 399 - 408 | IN ET AL., BR. J. CANCER, vol. 91, 2004, pages 1808 - 12 | SARKARLI, JNUTR., vol. 134, no. 12, 2004, pages 3493S - 3498S | DASMAHAPATRA ET AL., CLIN. CANCER RES., vol. 10, no. 15, 2004, pages 5242 - 52 | GILLSDENNIS, EXPERT. OPIN. INVESTIG. DRUGS, vol. 13, 2004, pages 787 - 97 | YANG ET AL., CANCER RES., vol. 64, 2004, pages 4394 - 9 | GOLDBERG ET AL., BLOOD, vol. 110, no. 1, 2007, pages 186 - 192 | THOMPSON ET AL., CLIN. CANCER RES., vol. 13, no. 6, 2007, pages 1757 - 1761 | S. M. BERGE ET AL.: "Pharmaceutical Salts", J PHARM SCI, vol. 66, 1977, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104 DOI: http://dx.doi.org/10.1002/jps.2600660104 | T. HIGUCHIW. STELLA: "Prodrugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14 | "BMC Genomics", vol. 15, 13 March 2014, article "Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma", pages: 190 | LIANG ET AL., JOURNAL OF BIOTECHNOLOGY, vol. 241, 2017, pages 136 - 146 | LEHAR, J. ET AL.: "Synergistic drug combinations tend to improve therapeutically relevant selectivity", NAT BIOTECH, vol. 27, no. 7, 2009, pages 659 - 666, XP055447444, DOI: 10.1038/nbt.1549 DOI: http://dx.doi.org/10.1038/nbt.1549 | RICKLES ET AL.: "Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening", MOL CANCER THERAPEUTICS, vol. 11, no. 7, 2012, pages 1432, XP055342591, DOI: 10.1158/1535-7163.MCT-11-0925 DOI: http://dx.doi.org/10.1158/1535-7163.MCT-11-0925 | SAIKI, A. Y. ET AL.: "MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways", ONCOTARGET, vol. 5, 2014, pages 2030 - 2043 |